Published in J Pharmacol Exp Ther on April 07, 2016
Imidazoline I2 receptors: An update. Pharmacol Ther (2017) 0.77
Trace amine-associated receptor 1 agonists RO5263397 and RO5166017 attenuate quinpirole-induced yawning but not hypothermia in rats. Behav Pharmacol (2017) 0.76
Role of intracellular Ca(2+) signaling in the antinociceptive and discriminative stimulus effects of the imidazoline I2 receptor agonist 2-BFI in rats. Psychopharmacology (Berl) (2017) 0.75
Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci (2015) 2.46
Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl⁻ homeostasis. Nat Neurosci (2013) 2.37
Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety (2009) 1.73
The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg (2010) 1.52
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther (2005) 1.26
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem (2009) 1.26
A preclinical comparison between different opioids: antinociceptive versus adverse effects. Pharmacol Biochem Behav (2005) 1.22
Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2003) 1.21
Gender-related differences in the antinociceptive properties of morphine. J Pharmacol Exp Ther (1996) 1.19
Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol (2000) 1.16
Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol (2013) 1.14
Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats. J Pain (2005) 1.10
Pain and suicidality: insights from reward and addiction neuroscience. Prog Neurobiol (2013) 1.08
Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J Pain Res (2011) 1.08
Apparent pA2 values of benzodiazepine antagonists and partial agonists in monkeys. J Pharmacol Exp Ther (1999) 1.07
Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I₂ receptor ligands. Eur J Pharmacol (2011) 1.05
Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain. Br J Pharmacol (2014) 1.03
Effects of imidazoline I₂ receptor ligands on morphine- and tramadol-induced antinociception in rats. Eur J Pharmacol (2011) 1.00
Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol (2008) 1.00
Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem (1995) 0.98
Effects of imidazoline I(2) receptor agonists and morphine on schedule-controlled responding in rats. Pharmacol Biochem Behav (2012) 0.97
Effects of imidazoline I2 receptor ligands on acute nociception in rats. Neuroreport (2012) 0.97
Receptor-selective antagonism of opioid antinociception in female versus male rats. Behav Pharmacol (2001) 0.93
Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats. Br J Pharmacol (2014) 0.93
Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys. Psychopharmacology (Berl) (1998) 0.92
Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. Brain Behav Immun (2015) 0.91
Idazoxan attenuates spinal cord injury by enhanced astrocytic activation and reduced microglial activation in rat experimental autoimmune encephalomyelitis. Brain Res (2008) 0.90
Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2006) 0.89
Combination opioid analgesics. Pain Physician (2008) 0.89
Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2007) 0.88
Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy. J Pharmacol Exp Ther (2010) 0.88
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses. J Pharmacol Exp Ther (2008) 0.85
Opposite age-dependent changes of alpha 2A-adrenoceptors and nonadrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) in the human brain: strong correlation of I2 with monoamine oxidase-B sites. J Neurochem (1993) 0.84
Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: interactions with oxycodone. Psychopharmacology (Berl) (2015) 0.84
Effects of serotonin (5-HT)1A and 5-HT2A receptor agonists on schedule-controlled responding in rats: drug combination studies. Psychopharmacology (Berl) (2010) 0.83
Protective effects of agmatine on lipopolysaccharide-injured microglia and inducible nitric oxide synthase activity. Life Sci (2012) 0.83
Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther (2014) 0.83
Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2014) 0.80
Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand. Eur J Pharmacol (2014) 0.80
In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I2 binding in relation to MAO: evidence for two distinct I2 binding sites. Neuropharmacology (2006) 0.79
Estrogens Suppress Spinal Endomorphin 2 Release in Female Rats in Phase with the Estrous Cycle. Neuroendocrinology (2015) 0.76
Effects of the imidazoline I2 receptor agonist 2-BFI on the development of tolerance to and behavioural/physical dependence on morphine in rats. Br J Pharmacol (2016) 0.76